Pfizer recently announced positive results from the BASIS study, the global phase 3 trial evaluating Hympavzi in young adults ...

On June 26, Pfizer Inc. (NYSE:PFE) declared that the Phase 3 BASIS research results showed that its medication HYMPAVZI (marstacimab) was superior to other inhibitors in treating hemophilia A or B ...

Pfizer on Thursday said the Phase 3 study of Hympavzi in patients 12 and older with hemophilia A or B with inhibitors met its primary endpoint and key secondary bleeding endpoints, showing a ...

“Hympavzi represents Pfizer’s latest contribution in more than 40 years of working to advance hemophilia care, as a generally well-tolerated treatment option that could offer bleed protection with a ...

Pfizer's hemophilia drug Hympavzi notches phase 3 win as pharma eyes label expansion By Kevin Dunleavy Jun 26, 2025 8:00am Pfizer hemophilia auto-injector labeling ...

On June 26, Pfizer announced positive topline results from its Phase 3 BASIS study evaluating HYMPAVZI (marstacimab) for individuals aged 12 to <75 years living with hemophilia A or B with inhibitors.

Pfizer Inc. announced positive topline results from the phase 3 BASIS study (NCT03938792) evaluating Hympavzi (marstacimab) for adults and adolescents living with haemophilia A or B with inhibitors.

Pfizer PFE announced that the phase III BASIS study evaluating its anti-TFPI inhibitor Hympavzi (marstacimab) for treating patients with hemophilia A or B with inhibitors met its primary endpoint ...